Minerva Neurosciences Shares Jump 200% On Positive Results From Phase IIB Study of MIN-101 Monotherapy

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.